Gujarat Terce Laboratories Limited (524314) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Gujarat Terce Laboratories Limited ₹39.67, price ₹35.16, upside +12.8%, quality 55 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Gujarat Terce Laboratories Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ₹6.80 – ₹89.21 · fair‑value band ₹26.62 – ₹56.93 · the ₹35.16 price screens below the ₹39.67 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow Gujarat Terce Laboratories in your weekly email
Every Wednesday you see whether Gujarat Terce Laboratories is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Gujarat Terce Laboratories Limited manufactures and markets medical and pharmaceutical preparations in India. The company offers branded and generic formulations covering various therapeutic, such as antibiotics, respiratory, nutraceuticals, gastrointestinal, anti-fungal, and others.
Show more
Gujarat Terce Laboratories Limited manufactures and markets medical and pharmaceutical preparations in India. The company offers branded and generic formulations covering various therapeutic, such as antibiotics, respiratory, nutraceuticals, gastrointestinal, anti-fungal, and others. It provides its products in various forms, such as tablets, capsules, oral liquids, injections, and ointments. The company also exports its products. Gujarat Terce Laboratories Limited was founded in 1985 and is based in Ahmedabad, India.
Stock analysis
Gujarat Terce Laboratories Limited (524314) currently trades at ₹35.16, while our model-based Fair Value estimate is ₹39.67, implying the stock looks roughly 11.4% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ₹62.07 per share, and 20 of the 24 models we run sit above the ₹35.16 price.
Bear case: the Asset-Based group reads lowest at ₹8.78, and 4 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹26.62 (bear) to ₹56.93 (bull), the price of ₹35.16 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Gujarat Terce Laboratories Limited reported revenue of ₹475M in FY2026 versus ₹401M in FY2022, a compound +4.3%/yr. Reported net income was ₹22.0M in FY2026, compounding +26.0%/yr from FY2022.
Key figures
Market cap ₹59.7M (≈ $620K) · P/E ratio 6.1 · P/S ratio 0.28 · EPS (TTM) ₹1.41 · Net margin 4.6% · Return on assets (EBIT) 5.4% · Operating margin 3.2% · Revenue (TTM) ₹356M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 38% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 13%, 524314 screens cheaper than that median.
Fair Value models
Bear ₹26.62Fair Value ₹39.67Bull ₹56.93
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹0.7200 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.78/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−5.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.5%
Start year 2021 (pandemic). Over 10 years: +6.6% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.2%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+19.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+19.2%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−12% → 7%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+8.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +4.1% a year for the price.
Compare Gujarat Terce Laboratories Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 569 stocks
Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score55 · Above median
Fair Value upside+29.2% · Top 25%
Profitability
Return on assets0.0% · Below median
Net margin (TTM)3.0% · Below median
Operating margin (TTM)3.2% · Below median
Growth and dividend
Revenue growth−28.2% · Bottom 25%
Dividend yield (TTM)0.0% · Bottom 25%
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Gujarat Terce Laboratories Limited (524314) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ₹39.67 versus a price of ₹35.16, about +13% upside (undervalued).
What is the fair value of 524314?
Our model-based fair value for Gujarat Terce Laboratories Limited is ₹39.67 (as of Sep 24, 2026), built from audited fundamentals. The current price: ₹35.16.
What is the quality score of 524314?
Gujarat Terce Laboratories Limited has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Gujarat Terce Laboratories Limited (524314)?
Our model-based price target is the fair value of ₹39.67 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario ₹26.62, optimistic scenario ₹56.93. It is a calculation from audited fundamentals, not an analyst target.
What is the Gujarat Terce Laboratories Limited stock forecast for 2026?
Our models put fair value at ₹39.67, about +13% upside versus a price of ₹35.16 (undervalued). Cautious scenario ₹26.62, optimistic scenario ₹56.93. The calculation is refreshed regularly with new filings.
What is the revenue of Gujarat Terce Laboratories Limited (524314)?
Gujarat Terce Laboratories Limited reported trailing-twelve-month revenue of about ₹356M (latest available figure, as of Sep 24, 2026).
What growth is priced into Gujarat Terce Laboratories Limited (524314)?
For today's price to be fair in a discounted-cash-flow model, Gujarat Terce Laboratories Limited would have to grow free cash flow by +8.5 % per year for five years (discount rate 10.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +13.5 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 524314 use?
Our models discount Gujarat Terce Laboratories Limited at 10.9 %: a base by market capitalisation (nano), damped by beta 0.47, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Gujarat Terce Laboratories Limited that is +8.5 % per year a year over ten years, using the same discount rate (10.9 %) and the same formula as our fair value.
How much growth has Gujarat Terce Laboratories Limited (524314) delivered so far?
Over the past 5 years revenue at Gujarat Terce Laboratories Limited grew +13.5 % a year. The price currently implies +8.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Gujarat Terce Laboratories Limited (524314) growing?
The median revenue growth in the sector is +7.6 % a year. That is the yardstick for the growth priced into Gujarat Terce Laboratories Limited (+8.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Gujarat Terce Laboratories Limited (524314)?
The free-cash-flow yield on the price is 6.15 %: that much free cash flow Gujarat Terce Laboratories Limited produces per unit of market value. When it exceeds the discount rate of our models (10.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Gujarat Terce Laboratories Limited (524314)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Gujarat Terce Laboratories Limited it is ₹39.67 per share (as of Sep 24, 2026), against a price of ₹35.16. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Gujarat Terce Laboratories Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 524314 trades below its calculated fair value: price ₹35.16, fair value ₹39.67, a gap of about +13% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 524314?
No. The price is what the market pays today (₹35.16); the fair value is what the company's own numbers justify (₹39.67). For Gujarat Terce Laboratories Limited the two are ₹4.51 per share apart. That gap is exactly why we show both numbers side by side.
How much is Gujarat Terce Laboratories Limited worth?
The market values Gujarat Terce Laboratories Limited at about ₹59.7M (market capitalisation, as of Sep 24, 2026). Per share that is ₹35.16; our models calculate a fair value of ₹39.67 per share.
What do the bullish and bearish scenarios say about 524314?
Our models span a range for Gujarat Terce Laboratories Limited: cautious scenario ₹26.62, base ₹39.67, optimistic ₹56.93 per share (as of Sep 24, 2026, price ₹35.16). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 524314?
Gujarat Terce Laboratories Limited trades at a price-to-earnings ratio of 6.1 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹39.67 is built from several models across several years.
How solid is the balance sheet of Gujarat Terce Laboratories Limited (524314)?
Balance-sheet figures for Gujarat Terce Laboratories Limited (as of Sep 24, 2026): debt of 0.00 per unit of equity. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is 524314 from its 52-week high?
Gujarat Terce Laboratories Limited trades at ₹35.16, about 38% below its 52-week high of ₹56.58 and 14% above the low of ₹30.90 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹39.67 is for.
Which stocks are comparable to Gujarat Terce Laboratories Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Gujarat Terce Laboratories Limited stock attractive at the current price?
The data as of Sep 24, 2026: price ₹35.16, calculated fair value ₹39.67 (+13%), Quality Score 55/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 524314 calculated?
We run Gujarat Terce Laboratories Limited through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹39.67, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Gujarat Terce Laboratories Limited currently trades 11 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Gujarat Terce Laboratories Limited (524314)?
The closing price on Oct 1, 2026 was ₹35.16. Our model-based fair value is ₹39.67, about +13% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Gujarat Terce Laboratories Limited right now?
A fairly wide model range (₹26.62 to ₹56.93) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Gujarat Terce Laboratories Limited
How large is the market capitalisation of Gujarat Terce Laboratories Limited (524314)?
The market capitalisation of Gujarat Terce Laboratories Limited is ₹59.7M (≈ $620K). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Gujarat Terce Laboratories Limited (524314)?
The price-to-sales ratio of Gujarat Terce Laboratories Limited is 0.28 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Gujarat Terce Laboratories Limited (524314)?
Earnings per share at Gujarat Terce Laboratories Limited are ₹1.41 (price ÷ EPS = P/E 6.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Gujarat Terce Laboratories Limited (524314)?
The net margin of Gujarat Terce Laboratories Limited is 4.6% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Gujarat Terce Laboratories Limited (524314)?
On an EBIT basis the return on assets of Gujarat Terce Laboratories Limited is 5.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Gujarat Terce Laboratories Limited (524314)?
The operating margin of Gujarat Terce Laboratories Limited is 3.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Gujarat Terce Laboratories Limited (524314)?
Revenue at Gujarat Terce Laboratories Limited is growing −28.2% versus a year earlier (3y avg +0.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Gujarat Terce Laboratories Limited (524314) carry?
The net debt of Gujarat Terce Laboratories Limited is ₹1.6M (fiscal year 2025, ≈ 0.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Gujarat Terce Laboratories Limited in the live analysis
One click puts Gujarat Terce Laboratories Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
